Replies to post #650509 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

How funny all the hype leading up to SNO and now poor alleged shareholders are demanding a retraction. Can't make it up.

[ilovetech]

Exactly, and it's no coincidence to see it timed over the holiday. Since it is a holiday weekend, I wouldn't expect the piece's audience primed to field information that's work related, as I wouldn't expect NWBO to be on the ready to retaliate on short notice. On the flipside, I believe the authors made a grave mistake by releasing the piece at the least opportune time to mute any potential, if any, impact it was meant to achieve. They could have released it on a Monday in advance of a full trading week. So they shot their bullet, and they've handed the timing and control of the rebuttal in the hands of NWBO. That's exactly where I'd want to be, and I'd wait until Monday morning to release the rebuttal.

ILT

[meirluc]

Ethan Chen's et al. second monumental error was embedded in the following
sentence of their review.

"The mOS for the Placebo group was not reported because 90% of subjects
crossed over from the placebo to the DCVax-L group upon determination of
progression (based on MRI) from treatment."

If I understand it correctly, Chen et al. were implying that of the 99 placebos, 90%
(about 89 patients) received DCVax-L after their progression when in fact only
64 of those original 99 placebos received the vaccine after progression. Instead, it was
90% of all 331 trial patients (296 patients) who received DCVax-L, with 232 treatment
patients receiving the vaccine before their progression and 64 receiving the vaccine after
progression.

Is there now any reason why the Ethan Chen group's review should not be withdrawn?